Mandanas buys Energy Vault (NRGV) shares worth $20,520
Investing.com - Stifel has raised its price target on Hinge Health Inc (NYSE:HNGE) to $66.00 from $63.00 while maintaining a Buy rating on the stock. The healthcare technology company, currently valued at $4.4 billion, has demonstrated impressive momentum with a 49.52% price return over the past six months.
The firm’s decision follows investor meetings with Hinge Health management at the Stifel Tech Summit and completion of a proprietary benefit manager survey that indicated significant momentum in the company’s business.
Stifel expects strong new client additions and retention during the seasonally strong selling period ending in October, along with continued yield improvements projected for 2026.
The research firm believes consensus revenue growth estimates of 20% for 2026 and 16% for 2027 are conservative, suggesting growth is more likely to approximate mid-20% over the next two years with higher than consensus margins.
Stifel’s proprietary benefit manager survey of 50 respondents highlighted asynchronous musculoskeletal care as an under-penetrated market with Hinge Health as the clear market leader, noting the stock currently trades at approximately 7.5 times 2026 revenue and 38 times free cash flow.
In other recent news, Hinge Health reported impressive second-quarter results that surpassed market expectations, leading the company to raise its 2025 revenue and EBIT guidance significantly. The company achieved revenue of $139.1 million in its first quarter as a public company, exceeding consensus estimates of $125.4 million and marking a 55% increase year-over-year. Following these strong earnings, several analyst firms adjusted their price targets for Hinge Health. Stifel increased its price target to $63, maintaining a Buy rating, while Citizens JMP raised its target to $65, continuing with a Market Outperform rating.
Piper Sandler also raised its price target to $70, up from $41, and maintained an Overweight rating, citing a strong outlook. The firm emphasized Hinge Health’s robust technology and commercial strategy, including its proprietary AI-powered 3D motion tracking technology, TrueMotion, and its FDA-cleared wearable device, Enso. Meanwhile, Baird initiated coverage on Hinge Health with a Neutral rating and a price target of $56, acknowledging the company’s compelling product offering. These developments reflect a positive response from the investment community to Hinge Health’s recent performance and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.